Every 8-K that Xilio Therapeutics, Inc. (XLO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow XLO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XLO filings page.
Xilio Therapeutics reported second quarter 2026 results and key pipeline updates. Collaboration and license revenue for the quarter was $18.7 million, up from $8.1 million a year earlier, while net loss narrowed to $6.4 million from $15.8 million. Cash and cash equivalents were $136.0 million as of June 30, 2026, and total stockholders’ equity increased to $72.3 million from $35.3 million at year-end 2025.
Operationally, Xilio received FDA clearance of its IND for XTX501, a bispecific PD‑1 / masked IL‑2, enabling initiation of a Phase 1/2 trial in metastatic NSCLC and select solid tumors in the second half of 2026, with initial Phase 1 data in NSCLC planned in the second half of 2027. The company is advancing IND‑enabling studies for masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1, with IND submissions planned in the second half of 2027, and continues a Phase 2 trial of efarindodekin alfa.
Xilio expects its current cash to fund operations into the first quarter of 2028, excluding up to $36.2 million in potential Series C warrant proceeds and up to $31.0 million in potential near‑term milestones and option fees under its AbbVie collaboration.
Xilio Therapeutics, Inc. reported governance and compensation updates from its 2026 annual stockholder meeting. To rebalance its staggered board, Daniel Curran, M.D. resigned as a Class II director immediately after being re-elected and was reappointed as a Class III director with no changes to his compensation.
Stockholders elected four Class II directors—Akintunde Bello, Ph.D., Dr. Curran, Robert Ross, M.D., and Yuan Xu, Ph.D.—to terms expiring at the 2029 annual meeting. They also ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
In addition, stockholders approved an amendment to the 2021 Stock Incentive Plan so that shares underlying outstanding prefunded warrants are included with outstanding common stock when calculating the plan’s annual evergreen increase, potentially affecting future equity award capacity.
Xilio Therapeutics reported first quarter 2026 results and pipeline progress. Collaboration and license revenue rose to $12.6 million from $2.9 million a year earlier, driven by AbbVie and Gilead agreements.
R&D expenses increased to $19.8 million, while G&A decreased to $6.9 million. Net loss narrowed to $9.5 million from $13.3 million. Cash and cash equivalents were $150.3 million as of March 31, 2026, helped by $37.3 million in net proceeds from a February 2026 follow-on offering.
The company achieved a $6.0 million development milestone under its AbbVie collaboration and now expects its cash, plus this milestone, to fund operations into early 2028. Xilio outlined plans for an IND filing and a Phase 1 trial for XTX501 in 2026, IND-enabling activities for multiple masked T cell engager programs, and an option data package for efarindodekin alfa in the first half of 2027.
Xilio Therapeutics, Inc. reported a board change and related director compensation details. On April 15, 2026, the board elected Cheryl R. Blanchard, Ph.D. as a Class III director with a term running through the 2027 annual meeting, and appointed her chair of the Compensation Committee and a member of the Audit Committee.
She will receive an annual cash fee of $40,000 for board service, plus $12,000 as Compensation Committee chair and $7,500 as an Audit Committee member. She will also receive an initial option to purchase 10,000 shares, vesting over three years, and become eligible for annual options to purchase 5,000 shares after six months of service. Each option will carry an exercise price equal to the Nasdaq closing price on the grant date and a ten-year term.
Dr. Blanchard replaces Christina Rossi, who resigned from the board and all committees effective April 15, 2026. The company states that Ms. Rossi’s resignation did not result from any disagreement with the company or its management.
Xilio Therapeutics reported much stronger 2025 results driven by collaboration revenue and new financing, while outlining progress across its masked immuno-oncology pipeline. Collaboration and license revenue rose to $43.8 million in 2025 from $6.3 million in 2024, mainly from AbbVie and Gilead agreements.
Research and development spending increased to $56.0 million as the company advanced XTX501 and multiple masked T cell engager programs, and net loss narrowed to $35.0 million from $58.2 million. Cash and cash equivalents were $137.5 million as of December 31, 2025, and Xilio expects this to fund operations through the end of 2027.
Xilio Therapeutics is implementing a 1-for-14 reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on March 13, 2026. Every fourteen issued and outstanding shares will be automatically reclassified into one share, with cash paid instead of fractional shares.
The company expects its common stock to begin trading on a split-adjusted basis on March 16, 2026 under the existing symbol XLO. The reverse split will not change the number of authorized shares or the par value but will reduce outstanding shares from approximately 73.5 million to approximately 5.2 million. A key aim is to help regain compliance with the Nasdaq Capital Market minimum bid price requirement.
Xilio Therapeutics is sharing an updated investor presentation highlighting its tumor‑selective immuno‑oncology pipeline, strategic partnerships and cash position. The company reports an estimated $137 in cash and cash equivalents as of December 31, 2025, plus $40M in gross proceeds from a February 2026 follow‑on offering and a cash runway through the end of 2027.
The presentation emphasizes wholly owned and partnered programs, including bispecific PD‑1/masked IL‑2 candidate XTX501, masked T cell engagers targeting PSMA+STEAP1 and CLDN18.2, masked IL‑12 efarindodekin alfa with Gilead, and masked anti‑CTLA‑4 vilastobart. Xilio outlines potential additional funding sources, including up to $36 in gross proceeds from Series C warrant exercises and a $75M option fee if Gilead licenses the IL‑12 program, alongside milestones with AbbVie and Gilead through 2027.
Xilio Therapeutics, Inc. reported that its stockholders approved an amendment to its restated certificate of incorporation to authorize a reverse stock split of its common stock. The reverse split may be implemented at a ratio between 1-for-2 and 1-for-30, at the sole discretion of the board of directors.
The proposal passed with 55,438,144 votes for, 1,521,271 against and 33,539 abstentions. Stockholders also approved a proposal to adjourn the special meeting if needed to obtain sufficient votes, with 55,461,067 votes for, 1,491,733 against and 40,154 abstentions.
Xilio Therapeutics has priced an underwritten offering of pre-funded warrants to strengthen its cash position. The company is selling pre-funded warrants to purchase 74,780,300 shares of common stock at $0.5349 per warrant, each exercisable for one share at an exercise price of $0.0001.
The transaction is expected to generate approximately $40.0 million in gross proceeds and about $37.1 million in net proceeds after underwriting discounts and expenses. Xilio plans to use the net proceeds to advance development of its product candidates, support working capital and for other general corporate purposes.
The warrants are immediately exercisable and remain outstanding until fully exercised, with ownership capped at 4.99% of outstanding common stock, or up to 19.99% at the holder’s election under specified notice and timing conditions. The offering is being conducted under Xilio’s effective Form S-3 shelf registration and is expected to close following customary conditions.
Xilio Therapeutics reported a preliminary estimate of approximately $137.5 million in cash and cash equivalents as of December 31, 2025. This figure is based on unaudited information and management estimates and is not a full set of financial results, so it may change once the year-end financial statements are completed and reviewed.
The company also announced a leadership change on its board. Sara M. Bonstein has been appointed chair of the board, succeeding Paul Clancy, who retired from the board effective January 6, 2026. The company stated that Mr. Clancy’s retirement did not result from any disagreement with the company or its management.
Xilio Therapeutics reported that stockholders approved two key compensation proposals at a special meeting. They approved a one-time repricing of certain outstanding employee stock options and the new 2025 Stock Incentive Plan, which had been previously adopted by the board subject to stockholder approval.
The repricing lowers the exercise price of affected options to $1.50 per share. For example, options for 2,198,212 shares held by the President and CEO previously had a weighted-average exercise price of $5.76, 848,172 shares held by the CFO had a price of $4.67, and 225,210 shares held by the Chief Medical Officer had a price of $4.10. If these repriced options are exercised within 12 months of November 21, 2025, the original higher exercise price must be paid, except in cases of death, disability, or a change in control.
The repricing proposal received 31,600,793 votes for and 1,690,846 against. The 2025 Plan was also approved, with 30,542,811 votes for and 2,876,155 against.
Xilio Therapeutics (XLO) filed an 8-K stating it announced financial results for the quarter ended September 30, 2025, along with other business highlights. The full details are in a press release furnished as Exhibit 99.1 and incorporated by reference.
The company specifies the information is furnished, not filed, and therefore not subject to liability under Section 18 of the Exchange Act, except as expressly incorporated by reference.
Xilio Therapeutics (XLO) furnished an Item 7.01 update, providing two press releases with new and updated clinical and preclinical data. The company highlighted Phase 2 results related to high plasma tumor mutational burden for vilastobart in combination with atezolizumab in microsatellite stable metastatic colorectal cancer.
Additional disclosures included portfolio updates: preclinical findings from its masked T cell engager platform and programs, updated Phase 1 data for efarindodekin alfa, and Phase 2 circulating tumor DNA data for vilastobart. These data were presented in poster sessions at the Society for Immunotherapy of Cancer 40th Annual Meeting. The information, including Exhibits 99.1 and 99.2, was furnished—not filed—under Regulation FD and is not subject to Section 18 liabilities nor incorporated by reference unless specifically stated.
Xilio Therapeutics, Inc. is moving its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective at the open of business on October 6, 2025, while continuing to trade under the symbol XLO. This change follows a prior notice from Nasdaq on April 8, 2025 that the company no longer met the $1.00 minimum bid price requirement for the Global Select tier. In connection with the transfer, Nasdaq granted Xilio an additional 180 calendar days, until March 30, 2026, for its stock to close at or above $1.00 for at least 10 consecutive business days to regain compliance. The company states that it is continuing to evaluate options to restore compliance with the minimum bid price rule.
Xilio Therapeutics disclosed that it has begun dosing patients in Phase 2 of an ongoing Phase 1/2 trial of efarindodekin alfa (XTX301), a tumor-activated IL-12 being tested as a monotherapy in certain advanced solid tumors. The company also reported achieving a $17.5 million development milestone under its license agreement with Gilead Sciences tied to this program and referenced updated data from the ongoing Phase 1 trial.
As of June 30, 2025, Xilio had $121.6 million in cash and cash equivalents. It now expects that this balance, together with the $17.5 million milestone, will fund operating and capital needs into the first quarter of 2027. Xilio expects to receive the milestone payment by the fourth quarter of 2025.
Xilio Therapeutics, Inc. reports that Nasdaq has notified the company it no longer meets the Nasdaq Global Select Market requirement to maintain at least $10.0 million in stockholders’ equity, after reporting stockholders’ equity of $7,069,000 in its Form 10-Q for the quarter ended June 30, 2025. The notice does not immediately affect trading of Xilio’s common stock. Xilio has 45 days, until October 6, 2025, to submit a plan to regain compliance, and Nasdaq may grant up to 180 additional days to show it meets the equity standard or allow a transfer to the Nasdaq Capital Market if that market’s listing criteria are satisfied.
The company also reminds investors that it previously received a Nasdaq notice on April 4, 2025 for failing to maintain the $1.00 minimum bid price, with an initial 180‑day cure period expiring on October 1, 2025, and that it remains out of compliance with this bid price requirement. Xilio states that it is evaluating options to regain compliance with Nasdaq listing rules.
Xilio Therapeutics, Inc. furnished an update on its business by announcing financial results for the quarter ended June 30, 2025 and related business highlights. The company did this through a press release dated August 14, 2025, which is attached as Exhibit 99.1.
The press release and related information are furnished, not filed, meaning they are not subject to certain Exchange Act liabilities and are only incorporated into other filings if specifically referenced.